Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(83.3%)
Phase 2
1(16.7%)
6Total
Phase 1(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00703066Phase 1Unknown

Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years

Role: lead

NCT00452088Phase 1Unknown

A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso

Role: lead

NCT00652275Phase 2Unknown

Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine

Role: lead

NCT00431808Phase 1Unknown

Safety and Immunogenicity of Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545])

Role: lead

NCT00424944Phase 1Unknown

Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine

Role: lead

NCT00469651Phase 1Unknown

Phase Ib Trial of MSP3 LSP in Children in Tanzania

Role: lead

All 6 trials loaded